BCL2 and acute lymphoblastic leukemia: Similarly, BCL-2 was expressed in 5/8 (62.5%) xenograft-passaged ETP-ALL patient samples and 7/7 (100%) ETP, near-ETP, or ETP/myeloid primary patient samples, but only 3/6 (50%) non-ETP T-ALL primary patient samples (Figure 1F).